Satralizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Myasthenia Gravis
Conditions
Generalized Myasthenia Gravis
Trial Timeline
Oct 19, 2021 → Sep 2, 2024
NCT ID
NCT04963270About Satralizumab
Satralizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Generalized Myasthenia Gravis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04963270. Target conditions include Generalized Myasthenia Gravis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05503264 | Phase 3 | Recruiting |
| NCT05271409 | Phase 3 | Recruiting |
| NCT04963270 | Phase 3 | Terminated |
Competing Products
20 competing products in Generalized Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| Quetiapine fumarate + Paroxetine | AstraZeneca | Phase 3 | 77 |